HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adjunctive use of controlled-release pregabalin in adults with treatment-resistant partial seizures: a double-blind, randomized, placebo-controlled trial.

AbstractOBJECTIVES:
To assess the efficacy and tolerability of add-on pregabalin controlled-release formulation (PGB-CR) (doses of 165 or 330 mg/day) in patients with partial-onset seizures (POS).
METHODS:
This was a randomized, double-blind (DB), parallel-group study of PGB-CR once-daily as adjunctive treatment in adults with treatment-resistant partial seizures. After an 8-week baseline period, eligible patients were randomized (1:1:1) to placebo, PGB-CR 165 mg, or PGB-CR 330 mg for 14 weeks, including a 2-week dose escalation. Primary endpoint was the loge -transformed 28-day seizure rate for all POS with observable component during the full 14-week double-blind treatment phase. Secondary endpoints included the 50% responder rate and percent change from baseline in 28-day POS rate.
RESULTS:
Three hundred twenty-three patients were randomized and received treatment; placebo (n = 110), PGB-CR 330 mg (n = 100), PGB-CR 165 mg (n = 113); and 287 (88.9%) completed the trial. The primary efficacy analysis result, expressed as percent reduction from placebo, was 13.1% and 1.0% for PGB-CR 330 mg and PGB-CR 165 mg, respectively, and was not statistically significant (p = 0.091, 0.908). The proportion of 50% responders was similar for placebo (35.8%) and 165 mg PGB-CR (37.8%) and nominally higher for 330 mg PGB-CR (45.9%, p = 0.125 compared to placebo). The LS mean estimates of the percent change from baseline for placebo (-5.7%) was nominally smaller than 165 mg PGB-CR (-15.0%, p = 0.540) and 330 mg PGB-CR (-31.5%, p = 0.079); however, the median percent changes from baseline were not as well differentiated (placebo, -35.4%; 165 mg PGB-CR, -38.0%; 330 mg PGB-CR -43.4%). Rates of adverse events (AEs) were low for placebo and study drug; the most frequent reported AEs were dizziness, somnolence, and fatigue, consistent with the immediate-release formulation.
SIGNIFICANCE:
Results from this trial did not demonstrate that PGB-CR is effective in reducing seizure frequency below that of placebo. Both doses of PGB-CR were shown to be safe and well-tolerated.
AuthorsJacqueline French, Christian Brandt, Daniel Friedman, Victor Biton, Lloyd Knapp, Verne Pitman, Marci Chew, Sarah Dubrava, Holly B Posner
JournalEpilepsia (Epilepsia) Vol. 55 Issue 8 Pg. 1220-8 (08 2014) ISSN: 1528-1167 [Electronic] United States
PMID24962242 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightWiley Periodicals, Inc. © 2014 International League Against Epilepsy.
Chemical References
  • Anticonvulsants
  • Delayed-Action Preparations
  • Pregabalin
  • gamma-Aminobutyric Acid
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anticonvulsants (administration & dosage)
  • Delayed-Action Preparations (administration & dosage)
  • Double-Blind Method
  • Drug Therapy, Combination
  • Epilepsies, Partial (diagnosis, drug therapy, physiopathology)
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Pregabalin
  • Prospective Studies
  • Treatment Outcome
  • Young Adult
  • gamma-Aminobutyric Acid (administration & dosage, analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: